What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.

Slides:

Advertisements

Similar presentations

HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.

Advertisements

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.

Immune Responses to HIV

Lack of Innate control of HIV

HIV-VACCINES. HIV - Vaccines  Vaccine development remains priority of AIDS research   Best hope for protection against HIV infection.

Bioe 109 Evolution Summer 2009 Lecture 1: Part II Evolution in action: the HIV virus.

" Scientific, Regulatory and Ethical Issues in

Lecture: HIV I.Motivation What can we learn when we apply evolutionary principles to our understanding of the of the HIV epidemic?? Can we use HIV to introduce.

Strategies for Targeting and Eradicating the HIV Reservoir

Introduction to Basic Science of HIV/AIDS. BREAKDOWN OF HIV RESEARCH BASIC SCIENCEBASIC SCIENCE Seeks the fundamental understanding of the biological,

Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.

HIV Science Update from Rome to Addis : Basic Science Coumba Toure Kane Dakar University Senegal.

Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.

Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.

Future directions in HIV basic science research The hunt for a cure.

Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.

HIV Vaccine Research & Development

HIV and AIDS. According to the Joint United Nations Programme on HIV/AIDS, as of the end of 2000, the following trends of the worldwide epidemic (or pandemic)

AIDS Vaccine R&D (post-AIDSVAX®). R&D challenges Products in development Funding AIDS vaccine R&D Access and advocacy.

Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.

IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.

AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.

The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.

Microbicide research in Africa: Partnership in Action Salim S. Abdool Karim, MD, PhD Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal.

Why study evolution?  Best conceptual framework for understanding origins of biodiversity  Adaptations that allow organisms to exploit their environment.

RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin.

HIV/AIDS vaccine development Lecture 10 Biomedical Engineering for Global Health.

An AIDS vaccine: challenges and progress Christine White-Ziegler Kahn Institute Fellow,“Biotechnology and World Health”

Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.

The French National Agency for Research on Aids and Viral Hepatitis – Clinical Research Legislation: A French Experience Ingrid Callies Legal Counsel in.

Molecular genetics of HIV-1 strains spreading in Russia Edward Karamov Ivanovsky Institute of Virology, Moscow 4th World Congress on Virology, 6-8 October.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --

Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,

Immunodeficiency syndromes. Classification Primary:rare,B,T & combined B &T deficits Secondary: in severe infection, immunosupression(CT,RT),malnutrition,DM,renal.

Using Molecular Information to Investigate the Evolutionary Origin of the HIV Virus.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

Evolution is the unifying concept of biology. Two Central Themes of Biology Adaptation - How and in what ways do organisms function and become better.

11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.

HIV & AIDS BY DR. MOHAMMED ARIF HEAD OF THE VIROLOGY UNIT ASSOCIATE PROFESSOR & CONSULTANT VIROLOGIST.

AIDS Vaccines: the basics CindraFeuer AVAC: Global Advocacy for HIV Prevention 20 April 2010 The HIV Research Catalyst Forum Baltimore, Maryland April.

ANIMAL MODELS FOR HIV VACCINES Girish N. Vyas, Ph.D. UCSF School of Medicine, San Francisco (UCSF) A quote from the keynote Address at the January, 2008.

Question An Exception - Not Baboons Only 2 of 279 baboons in Tanzania and Ethiopia were found to harbor SIV Subsequently shown to be SIVagm.

P1 Virology, Pathogenesis And Treatment Of HIV Infection.

Why study evolution?  Best conceptual framework for understanding origins of biodiversity  Adaptations that allow organisms to exploit their environment.

Infection and Disease Fungi Parasites Nosocomial infection Diagnosis of infectious disease.

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.

HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)

Retrovirus. Retroviridae –Retrovirus HTLV (human T-cell lymphotropic virus) –Lentivirus HIV.

25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.

THE IMMUNE RESPONSES TO VIRUSES

Track A Orientation Guido Silvestri, M.D. Track A Co-Chair

HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

XVII International AIDS Conference 3-8 August 2008, Mexico City, Mexico Abstract Session on: "Molecular Epidemiology and Diversity of HIV" 04 August 2008,

HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.

Large animal model Equine infectious anemia virus (EIAV) Visna-maedi virus (VMV) Caprine arthritis-encephalitis virus (CAEV)

HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK

Preclinical Pathway to Host-Directed Therapy for TB/HIV Co-Infection

State of HIV Cure Research

INPUT OF PMTCT TO ZERO NEW HIV INFECTION-CAMPAIGN IN RWANDA: Case of MUHIMA District Hospital By NTACYABUKURA Blaise, University of Rwanda, college of.

Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.

AIDS supplement.

HIV Vaccine Development

? Neutralizing Antibodies: Research pathways in 2013 and beyond

Viruses and Cancer.

Human Immunodeficiency Virus and Acquired Immunodeficiency Syndromes

Presentation transcript:

What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology Lecture at Academia Sinica 06 th October Taiwan

Therapy and prevention researchProphylactic and therapeutic vaccine research Number of people living with HIV (million) HIV biology and pathogenesis HIV-1 Identification HIV-1 Sequence HIV-1 Diversity Identification VIH-2 HIV-1 subtypes HIV-1 O Recombinants VIH-1 Origin of HIV HIV-1 N HIV-1 P CD4 Receptor Co-receptors HIV Reservoirs CD4 Depletion in gut Immune activation HIV Restriction factors HIV controllers Microbial Translocation HIV testing AZT Therapy PMTCT HAART Vaccine therapy Circumcision (risk reduction) AIDS 1st phase I trial VaxGen Trial STEP Trial « Thaï » trial SIV HIV Quantification ARV Resistance African epidemic M. Müller-Trutwin & F. Barré-Sinoussi Main milestones in 27 years of research on HIV

HIV Vaccine history August st phase I trial 2003 Data of the 1st phase III efficacy trial VaxGen Lack of efficacy of rgp120 definitively proven > 110 trials (10 Phase II/III) with 67 products ( volunteers) Candidate vaccine are usually safe and showed some degree of immunogenicity Sept STEP/Phambili phase IIb trial (HIV-1B gag, pol, nef / rAd5) Discontinued for lack of efficacy RV144 “Thaï”: ALVAC (gag/pol/env) + AidsVax (B/ErGp120) Oct Ongoing phase II trials (DNA+MVA, DNA+NYVAC, lipopeptides…) Modest Efficacy 31%

 Animal model limitations  Genetic Variability of HIV  Viral evasion of the immune system  Early establishment of viral reservoirs  Mechanisms of protection still undefined ???  Cell to cell transmission of the virus  HIV infects and alters key players of the immune system  Very rapid induction of dysfunctions in both innate and adaptative immune responses Défis scientifiques du vaccin (2) Think differently according to the knowledge pathogenesis 27 years after the discovery of AIDS virus, urgent need for a new vaccine strategies…